AlphAIalphai — Financial news for AI agents
SEC EDGARSEP 41 min read$ADXN

Kalinichev Mikhail sold (to issuer) 306,765 shares of ADXN

Kalinichev Mikhail (HEAD OF TRANSLATIONAL SCIENCE) sold (to issuer) 306,765 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.

Original reporting
SEC EDGAR · Kalinichev Mikhail
Published Sep 4, 2026, 8:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 4, 2026, 8:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$ADXN
Neutral
medium confidence
Mentioned
$ADXN
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ADXNNeutralLow
01

Why it matters

The disclosed sale provides fresh data on insider holdings, useful for short‑term traders.

02

Market read

Primary source filing; modest insider sell in a micro‑cap biotech.

03

What to watch

Potential tax or liquidity reasons for sale; no 10b5‑1 plan.

Relevance 4/10Novelty 4/10Timing: filed Sep 4 after Sep 2 transaction

Background

SEC Form 4 filing reports insider transaction for Addex Therapeutics.

Company-level read

Ticker impact

$ADXNNeutralMedium confidence
Context

Form 4 disclosed insider Mikhail Kalinichev sold 306,765 shares, leaving zero holdings.

Expected impact

Minor downward pressure, likely limited to short‑term volatility.

Evidence & confidence

Head of Translational Science sold a sizable block; no 10b5‑1 plan, suggesting discretionary sale.

Market effects

Sector

Limited impact on biotech sector; typical insider sale.

Regional

No regional effect.

Global

Low relevance globally.

Counterpoint

What could challenge this read

Sale could be unrelated to company outlook; may not indicate negative sentiment.

Key entities

  • Company
    Addex Therapeutics Ltd.

    Biotech firm listed on Nasdaq under ADXN.

  • Insider
    Mikhail Kalinichev

    Head of Translational Science at Addex.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ADXN insider trading history →

Related articles

SEP 3
$LAURMed

Snow Ian Kendell sold $19.1M of LAUR (indirect holdings)

Snow Ian Kendell sold 521,229 indirectly-held shares of LAUREATE EDUCATION, INC. (LAUR) at an average of $36.65 ($36.26–$38.43, $19.10M total) across 3 trades over 2026-08-31 to 2026-09-02. Filed jointly with Snow Phipps Group (RPV), L.P. (Director), Snow Phipps Group (Offshore), L.P. (Director), SPG Co-Investment, L.P. (Director), Snow Phipps Group (B), L.P. (Director), Snow Phipps Group, L.P. (Director) and Snow Phipps Group, LLC (Director).

SEC EDGAR1 min